SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
October 6, 2014
CAPRICOR THERAPEUTICS, INC.
(Exact name of Registrant as Specified
in its Charter)
|(State or other jurisdiction
8840 Wilshire Blvd., 2nd Floor, Beverly
(Address of principal executive offices)
(Registrant’s telephone number,
including area code)
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
New Planned Clinical Programs
Clinical Program for the Treatment of Duchenne Muscular Dystrophy
On October 6, 2014, Capricor Therapeutics, Inc. (the "Company")
issued a press release announcing plans to pursue a clinical program for the treatment of Duchenne Muscular Dystrophy with cardiosphere-derived
cells (CDCs). This press release announced the intention of the Company to pursue plans for a clinical program to treat patients
affected by the disorder using the Company’s lead product candidate, CAP-1002. A copy of the press release is attached hereto
as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
Clinical Program for the Treatment of Post-Acute Heart Failure
On October 9, 2014, the Company issued a press release announcing
plans to pursue a clinical program using Cenderitide for the treatment of post-acute heart failure using the Insulet Delivery Technology.
This press release described the Investigator-Initiated Research Support Agreement with Insulet Corporation and additional plans
associated with the planned clinical trial. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated
by reference into this Item 8.01 of this Current Report on Form 8-K.
|Item 9.01.||Financial Statements and Exhibits.
|99.1||Press Release, dated October 6, 2014, announcing plans to pursue a clinical program for Duchenne Muscular Dystrophy with cardiosphere-derived
|99.2||Press Release, dated October 9, 2014, announcing plans to pursue a Cenderitide clinical program and entry into Investigator-Initiated
Research Support Agreement with Insulet Corporation.|
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
||CAPRICOR THERAPEUTICS, INC.
|Date: October 9, 2014
||/s/ Linda Marbán, Ph.D.
||Linda Marbán, Ph.D.
||Chief Executive Officer